Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare?. Issue 6 (11th November 2016)

• Record Type: Journal Article
• Authors: Krieger, David; Schönfeld, Nicolas; Vesenbeckh, Silvan; Bettermann, Gudrun; Bauer, Torsten Thomas; Rüssmann, Holger; Mauch, Harald
• Is Part Of: European respiratory journal. Volume 48:Issue 6(2016)
• Page Start: 1803
• Page End: 1804
• Publication Date: 2016-11-11
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.01420-2016
• Languages: English
• ISSNs: 0903-1936

Abstract

Delamanid, a new agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis, has strong in vitro activity against Mycobacterium tuberculosis, including multidrug resistant (MDR) strains [1]. The drug has been proven to be effective in treatment of MDR tuberculosis (MDR-TB) patients [2–5]. Delamanid is pharmacologically characterised by an excellent intracellular bactericidal activity and a high accumulation rate [6]. Delamanid shows low minimal inhibitory concentrations in vitro against M. avium-intracellulare strains http://ow.ly/xDiM304ul7O